— CASGEVY™ approved in the U.S., European Union, Great Britain, the Kingdom of Saudi Arabia and Bahrain — The post CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results appeared first on Bio Tech Winners. CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy The post Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy appeared first on Bio Tech Winners. Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy
Mr. Huff was the Former CEO of LabCorp Diagnostics and joins with significant executive experience and a proven track record in medical diagnostics and healthcare Mr. Huff was the Former CEO of LabCorp Diagnostics and joins with significant executive experience and a proven track record in medical diagnostics and healthcare The post Diagnostics Industry Leader… Diagnostics Industry Leader Gary Huff Appointed to Biomerica Strategic Advisory Board
JUPITER, Fla. and NES-ZIONA, Israel, Feb. 21, 2024 (GLOBE NEWSWIRE) — Dyadic International, Inc. („Dyadic“ or the „Company“) (NASDAQ: DYAI), a global biotechnology company specializing in advanced microbial platforms for protein development and bioproduction and meeting clinical needs, and Israel Institute for Biological Research (IIBR) announced it has advanced its collaboration with the Israel Institute… Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions
– Innovative design enables five-minute pegfilgrastim-cbqv delivery time – The post Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv appeared first on Bio Tech Winners. Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv
Management will also participate in two upcoming healthcare conferences Management will also participate in two upcoming healthcare conferences The post Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024 appeared first on Bio Tech Winners. Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
Caroline Germa, M.D., an accomplished senior executive and medical oncologist, brings over 25 years of pharmaceutical and drug development expertise The post Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer appeared first on Bio Tech Winners. Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer
In a recent study published in the Journal of Biomedical Optics, researchers from the Indian Institute of Technology Indore unveiled a groundbreaking advancement—a compact and cost-effective PA sensing instrument designed specifically for biomedical tissue diagnosis. This proof-of-concept study employs low-cost diode laser. It represents a crucial step towards bridging the gap between laboratory research and clinical applications. The newly developed instrument integrates multiple laser diodes within a compact casing, alongside a custom-built pulsed current supply unit. This setup ensures efficient PA excitation, generating precise 25 nanosecond pulses at a frequency of 20 kHz. Subsequent data analysis involved calculating frequency spectra to quantitatively assess tissue properties. The results revealed distinct spectral patterns corresponding to different tissue types. For instance, fibrocystic breast disease exhibited a dominant frequency peak around 1.60 MHz, indicative of increased tissue density due to heightened glandular and stromal…
The National Institutes of Health (NIH) has launched a clinical trials network to evaluate emerging technologies for cancer screening. The Cancer Screening Research Network (CSRN) will support the Biden-Harris administration’s Cancer Moonshot? by investigating how to identify cancers earlier, when they may be easier to treat. Eight groups have received funding from the National Cancer Institute (NCI), part of NIH, to carry out the initial activities of the network. In 2024, the network will launch a pilot study, known as the Vanguard Study on Multi-Cancer Detection, to address the feasibility of using multi-cancer detection (MCD) tests in future randomized controlled trials. MCDs are blood tests that can screen for several types of cancers. The study will enroll up to 24,000 people to inform the design of a much larger randomized controlled trial. This larger trial will evaluate whether the benefits…
COPENHAGEN, Denmark, February 21, 2024 – Bavarian Nordic A/S (OMX: BAVA) today reports preliminary, unaudited financial results for 2023 and financial guidance for 2024. Furthermore, the Company provides an update on its R&D priorities. The post Bavarian Nordic delivered record financial results in 2023 appeared first on Bio Tech Winners. Bavarian Nordic delivered record financial results in 2023
